Genexine, Inc. (KOSDAQ:095700)
South Korea · Delayed Price · Currency is KRW 2,725.00
-265.00 (-8.86%)
Sep 22, 2026, 3:30 PM KST
Genexine Market Cap
Genexine has a market cap or net worth of 135.98 billion as of September 21, 2026. Its market cap has decreased by -45.34% in one year.
Market Cap
135.98B
Enterprise Value
n/a
Revenue
5.81B
Ranking
n/a
PE Ratio
n/a
Stock Price
2,725.00
ChartMarket Cap Chart
Since September 15, 2009, Genexine's market cap has increased from 109.02B to 135.98B, an increase of 24.73%. That is a compound annual growth rate of 1.31%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 21, 2026 | 135.98B | -36.18% |
| Dec 30, 2025 | 213.07B | -12.27% |
| Dec 30, 2024 | 242.86B | -40.82% |
| Dec 28, 2023 | 410.35B | -12.73% |
| Dec 29, 2022 | 470.21B | -67.78% |
| Dec 30, 2021 | 1.46T | -52.47% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Bioneer | 220.16B |
| GC Cell | 213.84B |
| NeoImmuneTech | 193.29B |
| HLB Therapeutics | 177.16B |
| GC Genome | 160.12B |
| Anterogen.Co.,Ltd. | 145.79B |
| Helixmith | 138.14B |
| Vaxcell-Bio Therapeutics | 101.52B |